A detailed history of Alpha Centric Advisors LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 40,000 shares of ACAD stock, worth $589,600. This represents 0.52% of its overall portfolio holdings.

Number of Shares
40,000
Previous 100,000 60.0%
Holding current value
$589,600
Previous $1.63 Million 62.15%
% of portfolio
0.52%
Previous 1.34%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$15.14 - $19.14 $908,400 - $1.15 Million
-60,000 Reduced 60.0%
40,000 $615,000
Q2 2024

Jul 25, 2024

BUY
$14.62 - $18.42 $804,100 - $1.01 Million
55,000 Added 122.22%
100,000 $1.63 Million
Q1 2024

Apr 24, 2024

BUY
$17.79 - $30.86 $338,010 - $586,340
19,000 Added 73.08%
45,000 $832,000
Q4 2023

Feb 14, 2024

SELL
$20.78 - $31.77 $498,720 - $762,480
-24,000 Reduced 48.0%
26,000 $814,000
Q4 2022

Feb 07, 2023

BUY
$14.2 - $18.63 $710,000 - $931,500
50,000 New
50,000 $796,000
Q3 2022

Nov 08, 2022

SELL
$14.11 - $18.27 $726,665 - $940,905
-51,500 Closed
0 $0
Q4 2021

Feb 25, 2022

SELL
$16.79 - $27.09 $369,380 - $595,980
-22,000 Reduced 29.93%
51,500 $1.2 Million
Q3 2021

Mar 09, 2022

BUY
$15.78 - $24.77 $946,800 - $1.49 Million
60,000 Added 444.44%
73,500 $1.22 Million
Q2 2021

Mar 09, 2022

BUY
$19.4 - $27.42 $261,899 - $370,170
13,500 New
13,500 $329,000
Q1 2021

Mar 09, 2022

SELL
$25.02 - $54.99 $58,797 - $129,226
-2,350 Closed
0 $0
Q4 2020

Mar 11, 2022

SELL
$41.04 - $56.79 $32,832 - $45,432
-800 Reduced 25.4%
2,350 $126,000
Q3 2020

Mar 11, 2022

BUY
$36.42 - $57.0 $114,723 - $179,550
3,150 New
3,150 $130,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.